BioMotiv of Cleveland has added a powerhouse partner to advance its mission of accelerating breakthrough medical discoveries.
The biotech accelerator on Wednesday morning, Sept. 4, announced it has formed a strategic partnership with New York-based pharmaceutical giant Bristol-Myers Squibb Co. (NYSE: BMY) that will “will leverage the strengths of both organizations to develop new and innovative therapies for patients who need them most.”
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell .
Originally published September 4, 2019.